AllSci News
University of Washington receives USD 1.2m NIH R35 award for cardiovascular-diabetes research
The [University of Washington](https://app.allsci.com/organization/ASC-OH-0000000000030-1.0-1764853177) has received a USD 1.2 million NHLBI R35 award to investigate the lipoprotein mechanisms driving cardiovascular disease risk in youth with diabetes, reflecting sustained National Institutes of Health interest in closing the translational gap between metabolic biology and early vascular preventio
University of Virginia receives USD 1.44m NIH grant for type 1 diabetes alternative splicing research
Alternative splicing emerges as a mechanistic focus in type 1 diabetes risk research, with the University of Virginia receiving USD 1.44 million from NIDDK...
Artiva Bio raises USD 300m via share offering to support NK cell therapy pipeline
FDA agreement on a Phase 3 registrational trial design positions Artiva Biotherapeutics for a potential BLA submission in refractory rheumatoid arthritis by...
Bristol Myers Squibb adds EU approval for Sotyktu in active psoriatic arthritis
The European Commission has approved Sotyktu (deucravacitinib) for active psoriatic arthritis in adults, making Bristol Myers Squibb’s (NYSE: BMY) oral TYK2 inhibitor…
University of Washington receives USD 2.1m NIH award for spatial transcriptomics technology development
A USD 2.1 million NIH R01 award positions the University of Washington at the center of an emerging effort to overcome a fundamental throughput bottleneck...
National Eye Institute awards USD 1.03m to Houston Methodist for mitochondrial dysfunction AMD therapy
A preclinical program targeting mitochondrial dysfunction in dry age-related macular degeneration has received USD 1.03 million in NIH R56 funding from the...
Odyssey Therapeutics raises USD 304m via Nasdaq IPO, backed by TPG Life Sciences affiliate
An upsized raise of approximately USD 304 million positions Odyssey Therapeutics among the larger clinical-stage biotech listings of the current market...
Gilead's Q1'26 Earnings Call: Anito-cel poised for December PDUFA decision, three acquisitions near inflection points
Gilead Sciences' Q1 2026 earnings conference call, held on May 7, 2026, revealed a company simultaneously managing three major acquisition integrations...
enGene reports 54% CR in NMIBC pivotal cohort, but 12-month durability remains limited at 25%
enGene Therapeutics (Nasdaq: ENGN) reported updated interim data from the pivotal cohort of its LEGEND trial showing detalimogene voraplasmid achieved a 54%...
Entrada Therapeutics' ENTR-601-44 meets primary safety goals in Duchenne muscular dystrophy trial
Entrada Therapeutics reported topline results from Cohort 1 of the Phase I/II ELEVATE-44-201 study evaluating ENTR-601-44 in ambulatory pediatric patients...
ArriVent moving MUC16/NaPi2b-targeted ADC into trials against ovarian and endometrial cancers
ArriVent BioPharma (Nasdaq: AVBP), based in Newtown Square, Pennsylvania, announced IND clearance from the US FDA for ARR-002, a dual-target tetravalent...
Rznomics’ RZ-001 RNA-editing therapeutic earns FDA RMAT designation for hepatocellular carcinoma
Rznomics (KOSDAQ: 476830), a clinical-stage biopharmaceutical company based in South Korea, announced that the US FDA has granted Regenerative Medicine Advanced Therapy…
Ukko doses first participant in mRNA-LNP peanut allergy trial redirecting IgE to protective IgG response
Ukko, Inc., a Boston-based biotechnology company, has dosed the first participant in a Phase 1/2a clinical study evaluating UKK-0018 for peanut allergy,...
Anagram Therapeutics secures USD 250m strategic investment from Blackstone Life Sciences
Natick, Massachusetts-based Anagram Therapeutics has closed a USD 250 million strategic investment from Blackstone Life Sciences to advance ANG003, a...
ParcelBio raises USD 13m seed financing for next-gen mRNA platform, in vivo CAR-T for auto-immune diseases
San Francisco-based ParcelBio has raised USD 13 million in seed financing to advance its APEXm (Amplified and Prolonged EXpression mRNA) platform and a lead...
The AllSci Brief
Free, systematic R&D and deal news. Daily.